Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Aug;194(3):542-546.
doi: 10.1111/bjh.17522. Epub 2021 May 24.

Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis

Birgitte Tholin  1 , Waleed Ghanima  1   2   3 , Gunnar Einvik  2   4 , Bernt Aarli  5   6 , Eivind Brønstad  7   8 , Ole H Skjønsberg  2   9 , Knut Stavem  2   4   10
Affiliations
Multicenter Study

Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis

Birgitte Tholin et al. Br J Haematol. 2021 Aug.

Abstract

Infection with coronavirus disease-2019 (COVID-19) may predispose for venous thromboembolism (VTE). There is wide variation in reported incidence rates of VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence of thrombotic complications in COVID-19 is uncertain. Here we present data on the incidence of VTE in both hospitalised and non-hospitalised patients from two ongoing prospective cohort studies. The incidence of VTE after diagnosis of COVID-19 was 3·9% [95% confidence interval (CI): 2·1-7·2] during hospitalisation, 0·9% (95% CI: 0·2-3·1) in the three months after discharge and 0·2% (95% CI: 0·00-1·25) in non-hospitalised patients, suggesting an incidence rate at the lower end of that in previous reports.

Keywords: anticoagulation; coronavirus disease-2019; epidemiology; incidence; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

BT, KS, BA, EB and OHS have no conflict of interest to disclose. GE has received unrestricted research grants from Boehringer Ingelheim and Novartis. WG has received honoraria from Amgen, MSD, Novartis and Pfizer, and research funding from Bayer, BMS/Pfizer and Novartis.

References

    1. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID‐19 is high and associated with a higher risk of mortality: a systematic review and meta‐analysis. EClinicalMedicine. 2020;29:100639. - PMC - PubMed
    1. Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AWS, Di Nisio M. Venous thromboembolism in patients with COVID‐19: systematic review and meta‐analysis. Thromb Res. 2020;196:67–74. - PMC - PubMed
    1. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. Br J Haematol. 2020;189:846–7. - PMC - PubMed
    1. Middeldorp S, Coppens M, Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost. 2020;18:1995–2002. - PMC - PubMed
    1. Lerum TV, Aaløkken TM, Brønstad E, Aarli B, Ikdahl E, Lund KMA, et al. Dyspnoea, lung function and CT findings three months after hospital admission for COVID‐19. Eur Respir J. 2020;10:2003448. - PMC - PubMed

Publication types

Substances